Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01746849 · ClinicalTrials.gov registry record · Phase 2
Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
A Phase 2 study of Multiple Myeloma and Leukemia, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
- 1
- Study location
NCT01746849: Active Phase 2 study of Multiple Myeloma and Leukemia, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01746849 is a Phase 2 study of Multiple Myeloma and Leukemia that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 82 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01746849, a Phase 2 study of Multiple Myeloma and Leukemia, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to help determine if palifermin and leuprolide acetate can help the immune system recover faster following a stem cell transplant. Blood stem cells are very young blood cells that grow in the body to become red or white blood cells or platelets. The transplant uses stem cells in the blood from another person. The donor can be a family member or a volunteer donor. This is called an allogeneic stem cell transplant. The investigators want to see if palifermin and leuprolide acetate can help the immune system recover faster after an allogenic transplant because experiments have shown they may be able to do this.
Primary Outcome
Will be documented by flow cytometry performed in the clinical lab on peripheral blood.
Conditions Studied
Interventions
- DRUG Thiotepa
- BIOLOGICAL Palifermin
- BIOLOGICAL Lupron
- PROCEDURE peripheral blood stem cell transplantation
- RADIATION Total-Body Irradiation (TBI)
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2012-12 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What the registry record for NCT01746849 still lists
NCT01746849 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 82 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (85% lower).
The record links to 4 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Thiotepa is the first listed.
NCT01746849 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01746849 about?
NCT01746849 is a clinical study titled "Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation". The purpose of this study is to help determine if palifermin and leuprolide acetate can help the immune system recover faster following a stem cell transplant. Blood stem cells are very young blood cells that grow in the body to become red or white blood cells or platelets. The transplant uses stem ...
What is the current status of trial NCT01746849?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2012-12. Estimated completion is 2026-12.
What conditions does trial NCT01746849 study?
This clinical trial studies the following conditions: Multiple Myeloma, Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma.
What interventions are being tested in trial NCT01746849?
The interventions under investigation include: Thiotepa (DRUG), Palifermin (BIOLOGICAL), Lupron (BIOLOGICAL), peripheral blood stem cell transplantation (PROCEDURE), Total-Body Irradiation (TBI) (RADIATION).
Who is sponsoring clinical trial NCT01746849?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01746849 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01746849's enrollment target sits among peer trials
82 196th of 438 higher than 241 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia